CARDIFF ONCOLOGY, INC. (CRDF) Return on equity 2016–2025
CARDIFF ONCOLOGY, INC. (CRDF) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-0.1%FY2025 · since FY2016: -198.3% → -0.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -0.1% | -0.0 pp |
| FY2024 | -0.1% | +0.0 pp |
| FY2023 | -0.1% | +36.3 pp |
| FY2022 | -36.4% | -16.2 pp |
| FY2021 | -20.1% | -5.1 pp |
| FY2020 | -15.1% | +209.4 pp |
| FY2019 | -224.5% | -61.2 pp |
| FY2018 | -163.2% | +219.6 pp |
| FY2017 | -382.8% | -184.5 pp |
| FY2016 | -198.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice